Item 6 of the Schedule 13D is amended and supplemented as follows: On October 14, 2025, the Master Fund and Perceptive Xontogeny each entered into a Voting and Support Agreement (the "Voting Agreement") with BioCryst Pharmaceuticals, Inc. ("BioCryst"). Pursuant to the Voting Agreement, the Master Fund and Perceptive Xontogeny each agreed to vote their respective shares of Common Stock in favor of the adoption of the merger agreement between BioCryst, the Issuer, and Axel Merger Sub, Inc. dated October 14, 2025 (the "Merger Agreement") with respect to the proposed acquisition of the Issuer by BioCryst (the "Merger") and the approval of the transactions contemplated thereby, and, subject to certain exceptions, not to transfer their shares of Common Stock prior to the earlier of the effective time of the Merger and the termination of the Merger Agreement. The Master Fund and Perceptive Xontogeny each also consented to the treatment of their respective shares of Series X Convertible Preferred Stock and Warrants as set forth in the Merger Agreement. The Voting Agreements will terminate upon the earlier of the effective time of the Merger, their termination by written notice from BioCryst, any amendment of any term or provision of the Merger Agreement that reduces the consideration to be received by holders of Common Stock, and the termination of the Merger Agreement. The foregoing description of the Voting Agreements is qualified in its entirety by reference to the terms of the agreements, the form of which is filed as Exhibit 8 to this Schedule 13D and incorporated by reference into this Item 6.

Item 7 of the Schedule 13D is amendmed and supplemented as follows: Exhibit 8 Form of Voting and Support Agreement (incorporated by reference to Exhibit 99.1 to Astria Therapeutics, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 14, 2025)